{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:53:44Z","timestamp":1781848424958,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ando.2023.11.003","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T07:42:45Z","timestamp":1701416565000},"page":"263-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Screening and management of metabolic complications of mTOR inhibitors in real-life settings"],"prefix":"10.1016","volume":"85","author":[{"given":"Pamela","family":"Spanjaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-6714","authenticated-orcid":false,"given":"Benjamin","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ando.2023.11.003_bib0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.15586\/jkcvhl.2015.43","article-title":"The Role of Everolimus in Renal Cell Carcinoma","volume":"2","author":"Meskawi","year":"2015","journal-title":"J Kidney Cancer VHL"},{"issue":"7","key":"10.1016\/j.ando.2023.11.003_bib0135","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9808","key":"10.1016\/j.ando.2023.11.003_bib0140","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ando.2023.11.003_bib0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the Role of mTOR in Cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ando.2023.11.003_bib0150","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with the use of mTOR inhibitors for cancer therapy","volume":"40","author":"Sivendran","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ando.2023.11.003_bib0155","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for Advanced Pancreatic Neuroendocrine Tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ando.2023.11.003_bib0160","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.molmet.2014.06.004","article-title":"Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo","volume":"3","author":"Kleinert","year":"2014","journal-title":"Molecular Metab"},{"issue":"11","key":"10.1016\/j.ando.2023.11.003_bib0165","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","article-title":"Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management","volume":"21","author":"Goldman","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ando.2023.11.003_bib0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ando.2006.11.002","article-title":"Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation","volume":"68","author":"Vantyghem","year":"2007","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"10.1016\/j.ando.2023.11.003_bib0175","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.tp.0000255679.81792.dd","article-title":"In vivo and in vitro effect of sirolimus on insulin secretion","volume":"83","author":"Marcelli-Tourvieille","year":"2007","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ando.2023.11.003_bib0180","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.ando.2023.11.003_bib0185","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.metabol.2007.06.016","article-title":"The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes","volume":"56","author":"Brown","year":"2007","journal-title":"Metab Clin Exp"},{"issue":"8","key":"10.1016\/j.ando.2023.11.003_bib0190","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ando.2023.11.003_bib0195","doi-asserted-by":"crossref","unstructured":"Bouillet B, Buffier P, Smati S, Archambeaud F, Cariou B, Verg\u00e8s B. Expert opinion on the metabolic complications of mTOR inhibitors.\/data\/revues\/00034266\/v79i5\/S0003426618311880\/[Internet]. 18 oct 2018 [cit\u00e9 12 janv 2020]; Disponible sur: https:\/\/www.em-consulte.com\/en\/article\/1251834.","DOI":"10.1016\/j.ando.2018.07.010"},{"issue":"261","key":"10.1016\/j.ando.2023.11.003_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.amcp.2017.07.004","article-title":"Prise en charge des dyslipid\u00e9mies: quelles nouvelles recommandations?","author":"Verg\u00e8s","year":"2017","journal-title":"Archives des Maladies du Coeur et des Vaisseaux - Pratique"},{"issue":"3","key":"10.1016\/j.ando.2023.11.003_bib0205","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"De Leo","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"10.1016\/j.ando.2023.11.003_bib0210","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ando.2023.03.011","article-title":"Glucocorticoid-induced hyperglycemia and diabetes: Practical points","volume":"84","author":"Descours","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"10.1016\/j.ando.2023.11.003_bib0215","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ando.2023.03.012","article-title":"Diabetes Induced by Immune Checkpoint Inhibitors (ICIs)","volume":"84","author":"Verg\u00e8s","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"10.1016\/j.ando.2023.11.003_bib0220","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13023-022-02385-8","article-title":"The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry","volume":"17","author":"Mulder","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.ando.2023.11.003_bib0225","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in Postmenopausal Hormone-Receptor\u2013Positive Advanced Breast Cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"9861","key":"10.1016\/j.ando.2023.11.003_bib0230","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"9637","key":"10.1016\/j.ando.2023.11.003_bib0235","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ando.2023.11.003_bib0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12885-016-2993-7","article-title":"Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma","volume":"17","author":"Jebali","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ando.2023.11.003_bib0245","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1684\/bdc.2014.1887","article-title":"Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals","volume":"101","author":"Lombard-Bohas","year":"2014","journal-title":"Bull Can"},{"issue":"1","key":"10.1016\/j.ando.2023.11.003_bib0250","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1038\/s41467-019-11174-0","article-title":"A novel rapamycin analog is highly selective for mTORC1 in vivo","volume":"10","author":"Schreiber","year":"2019","journal-title":"Nat Commun"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623007448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623007448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T10:41:40Z","timestamp":1728470500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426623007448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0003426623007448"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2023.11.003","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening and management of metabolic complications of mTOR inhibitors in real-life settings","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2023.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}